Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety
Abstract Background Endometriosis is a complex chronic disease that affects approximately 10% of women of reproductive age worldwide and commonly presents with pelvic pain and infertility. Method & outcome measures A systematic review of the literature was carried out using the databases Pubmed,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Women's Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12905-022-02122-0 |
| _version_ | 1811198383507898368 |
|---|---|
| author | Jon-Benay Mitchell Sarentha Chetty Fatima Kathrada |
| author_facet | Jon-Benay Mitchell Sarentha Chetty Fatima Kathrada |
| author_sort | Jon-Benay Mitchell |
| collection | DOAJ |
| description | Abstract Background Endometriosis is a complex chronic disease that affects approximately 10% of women of reproductive age worldwide and commonly presents with pelvic pain and infertility. Method & outcome measures A systematic review of the literature was carried out using the databases Pubmed, Scopus, Cochrane and ClinicalTrials.gov in women with a confirmed laparoscopic diagnosis of endometriosis receiving progestins to determine a reduction in pain symptoms and the occurrence of adverse effects. Results Eighteen studies were included in the meta-analysis. Progestins improved painful symptoms compared to placebo (SMD = −0.61, 95% CI (−0.77, −0.45), P < 0.00001) with no comparable differences between the type of progestin. After median study durations of 6–12 months, the median discontinuation rate due to adverse effects was 0.3% (range: 0 − 37.1%) with mild adverse effects reported. Conclusion The meta-analysis revealed that pain improvement significantly increased with the use of progestins with low adverse effects. Systematic Review Registration PROSPERO CRD42021285026. |
| first_indexed | 2024-04-12T01:30:06Z |
| format | Article |
| id | doaj.art-c57bc4a440814318b9a1f2924248b915 |
| institution | Directory Open Access Journal |
| issn | 1472-6874 |
| language | English |
| last_indexed | 2024-04-12T01:30:06Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Women's Health |
| spelling | doaj.art-c57bc4a440814318b9a1f2924248b9152022-12-22T03:53:31ZengBMCBMC Women's Health1472-68742022-12-0122111610.1186/s12905-022-02122-0Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safetyJon-Benay Mitchell0Sarentha Chetty1Fatima Kathrada2Division of Pharmacology, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the WitwatersrandDivision of Pharmacology, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the WitwatersrandDivision of Clinical Pharmacy, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the WitwatersrandAbstract Background Endometriosis is a complex chronic disease that affects approximately 10% of women of reproductive age worldwide and commonly presents with pelvic pain and infertility. Method & outcome measures A systematic review of the literature was carried out using the databases Pubmed, Scopus, Cochrane and ClinicalTrials.gov in women with a confirmed laparoscopic diagnosis of endometriosis receiving progestins to determine a reduction in pain symptoms and the occurrence of adverse effects. Results Eighteen studies were included in the meta-analysis. Progestins improved painful symptoms compared to placebo (SMD = −0.61, 95% CI (−0.77, −0.45), P < 0.00001) with no comparable differences between the type of progestin. After median study durations of 6–12 months, the median discontinuation rate due to adverse effects was 0.3% (range: 0 − 37.1%) with mild adverse effects reported. Conclusion The meta-analysis revealed that pain improvement significantly increased with the use of progestins with low adverse effects. Systematic Review Registration PROSPERO CRD42021285026.https://doi.org/10.1186/s12905-022-02122-0EndometriosisProgestinsPain reliefAdverse effects |
| spellingShingle | Jon-Benay Mitchell Sarentha Chetty Fatima Kathrada Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety BMC Women's Health Endometriosis Progestins Pain relief Adverse effects |
| title | Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety |
| title_full | Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety |
| title_fullStr | Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety |
| title_full_unstemmed | Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety |
| title_short | Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety |
| title_sort | progestins in the symptomatic management of endometriosis a meta analysis on their effectiveness and safety |
| topic | Endometriosis Progestins Pain relief Adverse effects |
| url | https://doi.org/10.1186/s12905-022-02122-0 |
| work_keys_str_mv | AT jonbenaymitchell progestinsinthesymptomaticmanagementofendometriosisametaanalysisontheireffectivenessandsafety AT sarenthachetty progestinsinthesymptomaticmanagementofendometriosisametaanalysisontheireffectivenessandsafety AT fatimakathrada progestinsinthesymptomaticmanagementofendometriosisametaanalysisontheireffectivenessandsafety |